Approaches to hepatitis C treatment and cure using NS5A inhibitors
about
Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment optionsFlaviviral NS4b, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral interventionSafety and efficacy of daclatasvir in the management of patients with chronic hepatitis CRecent Advances in Antiviral Therapy for Chronic Hepatitis CNew era for management of chronic hepatitis C virus using direct antiviral agents: A reviewAsymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition.TRIM14 inhibits hepatitis C virus infection by SPRY domain-dependent targeted degradation of the viral NS5A proteinThe Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C.Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding.An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.Pharmacoinformatics approach for investigation of alternative potential hepatitis C virus nonstructural protein 5B inhibitors.Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy.Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment StrategiesNew treatments for chronic hepatitis C: an overview for paediatricians.Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions.Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094.Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
P2860
Q24658456-A96E6DDE-343C-4718-855D-43198DF9F2B7Q26314693-B9D80D22-6C15-49DD-A8ED-B02937FF13B9Q26745769-30007497-A435-4E9B-94ED-165438D5A2B1Q26750476-080F9B0C-7B84-4361-8ADB-C1BA494DCD03Q26800050-63E50F44-EC0A-4810-8469-E053C702456BQ27335920-8F8FFB57-B225-44F5-8DC8-8DF545B0CAD4Q27468803-46699F6E-C650-4E76-AF34-484DD05ED490Q33621649-FDB9CE73-EFCB-4933-A7FD-249518ADCBC1Q34481846-8E26CB4C-D508-4A02-B6CB-15F64BFF6E61Q34580799-C35E9CE0-3011-452E-9CA9-F8A5B1A49C74Q35100139-8DFD008E-FD96-43E4-8A00-E264C8128666Q35248674-E3C86A46-6273-47DD-A915-F997F5F45F62Q35774186-764F4E0F-4219-4BCE-BF78-1B59A360DA1CQ36173242-CB90275E-7CC4-40FB-BB41-51F930E0AD4CQ36981033-032623E7-4C6A-41C4-A42A-672A22FAA5B4Q38282842-082A5BC3-702B-47C1-86D7-C214E5889ACAQ38728564-4E90A6D4-4F83-416A-AC37-B4B6F31C4EDBQ39742470-DDAD10AC-754D-4F38-A97F-AA38ED010486Q56395991-9FA5CDD0-0F5C-4983-84A4-A9FA6954F70A
P2860
Approaches to hepatitis C treatment and cure using NS5A inhibitors
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Approaches to hepatitis C treatment and cure using NS5A inhibitors
@en
Approaches to hepatitis C treatment and cure using NS5A inhibitors.
@nl
type
label
Approaches to hepatitis C treatment and cure using NS5A inhibitors
@en
Approaches to hepatitis C treatment and cure using NS5A inhibitors.
@nl
prefLabel
Approaches to hepatitis C treatment and cure using NS5A inhibitors
@en
Approaches to hepatitis C treatment and cure using NS5A inhibitors.
@nl
P2093
P2860
P356
P1476
Approaches to hepatitis C treatment and cure using NS5A inhibitors
@en
P2093
Franck Amblard
James H Nettles
James J Kohler
Leda Bassit
Maryam Ehteshami
Richard A Stanton
Selwyn J Hurwitz
P2860
P356
10.2147/IDR.S36247
P407
P577
2014-03-05T00:00:00Z